Structure–Activity Relationship of 18F‑Labeled Phosphoramidate Peptidomimetic Prostate-Specific
Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging
of Prostate Cancer

Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry; Geruntho, Jonathan
J.; Galliher, Matthew S.; Beyer, Sophia K.; Choy, Cindy J.; Hopkins, Mark R.; Regan, Melanie; Blecha, Joseph E.; Skultetyova, Lubica; Drake, Christopher R.; Jivan, Salma; Barinka, Cyril; Jones, Ella
F.; Berkman, Clifford E.; VanBrocklin, Henry F.

doi:10.1021/acs.jmedchem.5b01850.s001

Structure–Activity Relationship of ¹⁸F‑Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer

journal contribution

posted on 2016-05-26, 00:00 authored by Shorouk Dannoon, Tanushree Ganguly, Hendry Cahaya, Jonathan J. Geruntho, Matthew S. Galliher, Sophia K. Beyer, Cindy J. Choy, Mark R. Hopkins, Melanie Regan, Joseph E. Blecha, Lubica Skultetyova, Christopher R. Drake, Salma Jivan, Cyril Barinka, Ella F. Jones, Clifford E. Berkman, Henry F. VanBrocklin

A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of increasing lipophilicity were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron emission tomography (PET) imaging agents for prostate cancer. To gain insight into their modes of binding, they were also cocrystallized with the extracellular domain of PSMA. All analogs exhibited irreversible binding to PSMA with IC₅₀ values ranging from 0.4 to 1.3 nM. In vitro assays showed binding and rapid internalization (80–95%, 2 h) of the radiolabeled ligands in PSMA(+) cells. In vivo distribution demonstrated significant uptake in CWR22Rv1 (PSMA(+)) tumor, with tumor to blood ratios of 25.6:1, 63.6:1, and 69.6:1 for [¹⁸F]4, [¹⁸F]5, and [¹⁸F]6, respectively, at 2 h postinjection. Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [¹⁸F]5 and [¹⁸F]6 as favorable candidates for future prostate cancer imaging clinical trials.